August 2013: Nimotuzumab in MOGA Australia
Medical Oncology Group of Australia
Similar Posts
July 2015: Innokeys Pte Ltd Consolidates Nimotuzumab Development by Acquiring Oncoscience AG
ByInnokeys
Innokeys Pte Ltd Consolidates Nimotuzumab Development by Acquiring Oncoscience AG • The acquisition enables Innokeys to fully lead clinical and commercial development…
Webinar – Treatment Optimization in Locally Advanced & Metastatic Pancreatic Cancer-Tailored Patient Approach with Targeted Therapy
ByInnokeys
Prof. Dr. Dirk Strumberg, Oncologist in Marien Hospital Herne, Germany
August 2015: Innokeys Pte Ltd attends Congress of Obstetrics and Gynecology Indonesia 2015
ByInnokeys
Innokeys Pte Ltd attends Congress of Obstetrics and Gynecology Indonesia 2015 Bandung, Indonesia (Augus 26, 2015) – Innokeys Pte Ltd attended the…
Update on Laryngeal Cancer
ByInnokeys
Speakers: 1. dr. Denny Satria Utama, Sp.T.H.T.L(K)., M.Si Med., FICS from Charitas Hospital Indonesia 2. Dr. dr. Fauziah Fardizza, Sp.T.H.T.K.L(K), FICS from…
New publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab
ByInnokeys
New publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab in combination with gemcitabine. The…